![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Preclinical characterization of ABI-4334, a novel,
highly potent core inhibitor for the treatment of chronic
hepatitis B virus infection
|
|
|
AASLD 2021 Nov 12-15
Xiang Xu, Michael Shen, Lida Guo, Ariel Tang, Nuruddin Unchwaniwala, Thilo J Heckrodt, Min Zhong, Michael A Walker, Michel Perron, William Delaney, Kathryn M Kitrinos
Assembly Biosciences, Inc., South San Francisco, CA, USA
![1214211](../images/121421/121421-4/1214211.gif)
![1214212](../images/121421/121421-4/1214212.gif)
![1214213](../images/121421/121421-4/1214213.gif)
![1214214](../images/121421/121421-4/1214214.gif)
![1214215](../images/121421/121421-4/1214215.gif)
![1214216](../images/121421/121421-4/1214216.gif)
![1214217](../images/121421/121421-4/1214217.gif)
![1214218](../images/121421/121421-4/1214218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|